Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Acurx Pharmaceuticals Inc (ACXP)

Acurx Pharmaceuticals Inc (ACXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,257
  • Shares Outstanding, K 2,085
  • Annual Sales, $ 0 K
  • Annual Income, $ -14,100 K
  • EBIT $ -9 M
  • EBITDA $ -9 M
  • 60-Month Beta -1.25
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.88

Options Overview Details

View History
  • Implied Volatility 0.00% (unch)
  • Historical Volatility 94.91%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 943.93% on 12/19/24
  • IV Low 0.00% on 12/02/25
  • Expected Move (DTE 41) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 0
  • Put/Call OI Ratio 0.77
  • Today's Open Interest 1,723
  • Open Int (30-Day) 1,723
  • Expected Range 3.29 to 3.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.01
  • Number of Estimates 1
  • High Estimate -1.01
  • Low Estimate -1.01
  • Prior Year -3.20
  • Growth Rate Est. (year over year) +68.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.17 +1.22%
on 12/03/25
5.79 -44.56%
on 11/11/25
-1.94 (-37.67%)
since 11/05/25
3-Month
3.17 +1.22%
on 12/03/25
8.34 -61.51%
on 10/08/25
-0.87 (-21.32%)
since 09/05/25
52-Week
3.17 +1.22%
on 12/03/25
25.00 -87.16%
on 01/06/25
-12.24 (-79.22%)
since 12/05/24

Most Recent Stories

More News
New to The Street Show #702 Airs Today on Bloomberg at 6:30 PM EST

The show airs as sponsored programming with TV commercials by Synergy CHC, Sustainable Green Team, Laser Pharmaceuticals, and PetVivo.

RDZN : 1.6500 (-1.79%)
ACXP : 3.21 (-7.76%)
NRXP : 2.36 (-3.28%)
AERT : 0.6340 (-0.80%)
CISO : 0.4577 (-13.63%)
Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals

STATEN ISLAND, N.Y. , Nov. 18, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...

ACXP : 3.21 (-7.76%)
New to The Street Airs Landmark Show #700 Today at 6:30 PM ET on Bloomberg Television

Featured companies include Lionscrest Advisors, DataVault AI (NASDAQ:DVLT), Pudgy Penguins (PENGU)), Peer To Peer Network (OTC:PTOP), and Acurx Pharmaceuticals (NASDAQ:ACXP).

PTOP : 0.0708 (-5.47%)
ACXP : 3.21 (-7.76%)
DVLT : 1.7000 (-8.60%)
Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update

STATEN ISLAND, N.Y. , Nov. 12, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics...

ACXP : 3.21 (-7.76%)
Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens

STATEN ISLAND, N.Y. , Nov. 10, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule...

ACXP : 3.21 (-7.76%)
Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference

STATEN ISLAND, N.Y. , Oct. 28, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), is a late-stage biopharmaceutical company developing a new class of antibiotics...

ACXP : 3.21 (-7.76%)
Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update

STATEN ISLAND, N.Y. , Oct. 27, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics...

ACXP : 3.21 (-7.76%)
New to The Street to Broadcast Nationwide on Bloomberg TV Tonight at 6:30 PM EST Featuring Roadzen, Spartan Equipment, XION, Metaterra, and YY Group

The show broadcasts as sponsored programming with featured commercials by Laser Photonics (NASDAQ:LASE), PetVivo (OTCQB:PETV), Aeries Technology (NASDAQ:AERT), Acurx Pharmaceuticals (NASDAQ:ACXP), and...

PETV : 1.0950 (-2.23%)
LASE : 2.79 (-4.45%)
ACXP : 3.21 (-7.76%)
AERT : 0.6340 (-0.80%)
YYGH : 0.2865 (+1.02%)
DVLT : 1.7000 (-8.60%)
New to The Street Show #694 to Broadcast Tonight at 6:30 PM EST as Sponsored Programming on Bloomberg TV Featuring Stardust Power (NASDAQ:SDST), Spartan Equipment, Roadzen (NASDAQ:RDZN), Aeries Technology (NASDAQ:AERT), and XION

NEW YORK CITY, NY / ACCESS Newswire / October 18, 2025 / New to The Street, one of the nation's longest-running business television brands airing as sponsored programming on Bloomberg Television (6:30...

RDZN : 1.6500 (-1.79%)
SNYR : 1.8350 (-1.87%)
PETV : 1.0950 (-2.23%)
SDST : 3.51 (-2.77%)
ACXP : 3.21 (-7.76%)
AERT : 0.6340 (-0.80%)
SGTM : 0.0800 (-7.19%)
Meet the Companies - New to The Street's Accredited Investor Event Returns October 21-22 at Hudson Yards, NYC

NEW YORK CITY, NEW YORK / ACCESS Newswire / October 10, 2025 / New to The Street, one of the nation's longest-running business television brands airing as sponsored programming on Fox Business and Bloomberg,...

RDZN : 1.6500 (-1.79%)
AREB : 1.0700 (-2.73%)
SNYR : 1.8350 (-1.87%)
PETV : 1.0950 (-2.23%)
MUSQ : 27.79 (+0.57%)
NTHI : 9.17 (-1.93%)
ACXP : 3.21 (-7.76%)
DVLT : 1.7000 (-8.60%)

Business Summary

Acurx Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. It focused on developing new antibiotics to treat infections. Acurx Pharmaceuticals Inc. is based in STATEN ISLAND, N.Y.

See More

Key Turning Points

3rd Resistance Point 3.61
2nd Resistance Point 3.53
1st Resistance Point 3.37
Last Price 3.21
1st Support Level 3.12
2nd Support Level 3.04
3rd Support Level 2.88

See More

52-Week High 25.00
Fibonacci 61.8% 16.66
Fibonacci 50% 14.09
Fibonacci 38.2% 11.51
Last Price 3.21
52-Week Low 3.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar